Aclaris Therapeutics Inc (ACRS)

$ACRS 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

CEO

Neal Walker

Exchange

NASDAQ

Website

www.aclaristx.com

$10M

Total Revenue

59

Employees

$1B

Market Capitalization

-11.83

Price/Earning ratio

Company News

Aclaris Therapeutics, Inc. Expected to Earn Q3 2022 Earnings of ($0.39) Per Share (NASDAQ:ACRS)

5d ago, source: Defense World

Equities researchers at SVB Leerink lowered their Q3 2022 earnings per share estimates for shares of Aclaris Therapeutics in ...

Cantor Fitzgerald Weighs in on Aclaris Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:ACRS)

5d ago, source: Defense World

Research analysts at Cantor Fitzgerald boosted their FY2022 earnings estimates for Aclaris Therapeutics in a research report ...

Aclaris Therapeutics Expands Leadership Team

12d ago, source: YAHOO!Finance

Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS), ...

Q3 2022 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lowered by Analyst

5d ago, source: ETF Daily News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) – Stock analysts at William Blair lowered their Q3 2022 earnings estimates for Aclaris Therapeutics in a report issued on Wednesday ...

Aclaris: Q2 Earnings Snapshot

9d ago, source: Kansas City Star

Aclaris Therapeutics Inc. (ACRS) on Wednesday reported a loss of $20.5 million in its second quarter. On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 31 cents.

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

10d ago, source: Stockhouse

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

Cantor Fitzgerald Weighs in on Aclaris Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:ACRS)

5d ago, source: ETF Daily News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) – Research analysts at Cantor Fitzgerald increased their FY2022 EPS estimates for Aclaris Therapeutics in a report issued on Thursday ...

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

10d ago, source: FOX40

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...

My Portfolio